×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: chronic | hives | Xolair | omalizumab | csu

Drug Found to Help Chronic Hives

Wednesday, 26 June 2013 09:24 AM

Swiss drugmaker Novartis said its drug omalizumab significantly improved itch in patients with a severe form of hives, according to a late-stage study.

The second of three late-stage studies found that more than one third of patients with chronic spontaneous urticaria (CSU) who were treated with the drug were completely itch and hive-free after 12 weeks compared to 5 percent of patients on placebo.

Omalizumab, which is also known as Xolair, is already approved for treating severe asthma. Novartis said it was on track to submit omalizumab for regulatory approval in patients with CSU later this year.

© 2022 Thomson/Reuters. All rights reserved.


Health-News
Swiss drugmaker Novartis said its drug omalizumab significantly improved itch in patients with a severe form of hives, according to a late-stage study.The second of three late-stage studies found that more than one third of patients with chronic spontaneous urticaria (CSU)...
chronic,hives,Xolair,omalizumab,csu
97
2013-24-26
Wednesday, 26 June 2013 09:24 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved